AURKA and breast cancer: Given that the average IC50 values of the drugs targeting TYMS (e.g. Methotrexate), which are already approved chemotherapy drugs for breast cancer [38], were 64.155\documentclass[12pt]{minimal}\usepackage{amsmath}\usepackage{wasysym}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{amsbsy}\usepackage{upgreek}\usepackage{mathrsfs}\setlength{\oddsidemargin}{-69pt}\begin{document}$\mathrm{\mu}$\end{document}M in 50 breast cancer cell-line samples, these results highlights that the drugs targeting KIF11 and AURKA also could be effective individualized chemotherapy drugs for breast cancer.